Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refractory to conventional therapies [VALUTAZIONE DELL'EFFICACIA DEL TRATTAMENTO ASSOCIATO [90Y-DOTA, TYR(3)]OCTREOTATE E [177Lu-DOTA, TYR(3)]OCTREOTATE, IN PAZIENTI CON NEOPLASIE NEUROENDOCRINE ESPRIMENTI RECETTORI PER LA SOMATOSTATINA REFRATTARIE AI TRATTAMENTI CONVENZIONALI].

Trial Profile

Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refractory to conventional therapies [VALUTAZIONE DELL'EFFICACIA DEL TRATTAMENTO ASSOCIATO [90Y-DOTA, TYR(3)]OCTREOTATE E [177Lu-DOTA, TYR(3)]OCTREOTATE, IN PAZIENTI CON NEOPLASIE NEUROENDOCRINE ESPRIMENTI RECETTORI PER LA SOMATOSTATINA REFRATTARIE AI TRATTAMENTI CONVENZIONALI].

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs 90Y DOTATATE (Primary) ; Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top